Author Archives: Patricia Inacio PhD

Mouse Model for Angelman Reveals Touchscreen Learning Deficits

A mouse model for Angelman and Down syndrome has revealed deficits in touchscreen learning, suggesting that assessing this type of outcome may help identify effective therapies. The study, “Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities,” appeared in the journal…

Ovid’s OV101 Earns FDA’s Fast Track Designation

The U.S. Food and Drug Administration (FDA) awarded a fast track designation to Ovid Therapeutics’ OV101 for the treatment of Angelman syndrome. The designation allows for expedited development and review of therapeutics for serious diseases with high unmet medical need. “This designation is an important milestone for both Ovid…